Breadcrumb

[A18-18] Cabozantinib (renal cell carcinoma) - Second Addendum to Commission A17-56

Overview

Overview

Commission: Commission awarded on 2018-03-13 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A17-56  [PDF, 118 kB]Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A18-37] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-56] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2018-04-05 Addendum to Commission A17-56 118 kBPDFdownload file

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2018-04-05 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close